Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 10/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | MMP7 known ✓ | P09237 | 6/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 16/20 | 0.41 |
| ▸ | MMP3 | P08254 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11130193 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL60916 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL1683449 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5183324 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5086708 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL875996 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL11576013 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL82688 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5088573 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL1011374 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | POLYAMYNA NANOTECH INC. (CA) | 2026-05-28 | — | — | US | claimed |
| US-12546718-B2 | Silane-fluorophore complex indicator fluoride measurement | HACH COMPANY (US) | 2026-02-10 | — | — | US | claimed |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | claimed |
| US-20250383290-A1 | DIOXA-SILOLO COUMARIN DERIVATIVES INDICATOR FLUORIDE MEASUREMENT | HACH CO (US) | 2025-12-18 | — | — | US | claimed |
| US-20250359545-A1 | Anti-pathogenic aerosol compositions | SQUIRE KENT PTY LTD (AU) | 2025-11-27 | — | — | US | claimed |
| EP-4642858-A1 | COATING COMPOSITION FOR COVERING A SURFACE AREA COMPRISING TUNGSTEN ON A SEMICONDUCTOR DEVICE DURING AN ATOMIC LAYER DEPOSITION PROCESS | BASF SE (DE) | 2025-11-05 | — | — | EP | claimed |
| EP-4594442-A1 | EXTENDED RELEASE ASPHALTENE INHIBITOR COMPOSITION | ChampionX LLC (US) | 2025-08-06 | — | — | EP | claimed |
| US-12359129-B2 | Liquid crystal material applied to multi-response-mode smart window and application thereof | HARBIN INSTITUTE OF TECHNOLOGY (CN) | 2025-07-15 | — | — | US | claimed |
| US-12359113-B2 | Method for dispersing kinetic hydrate inhibitors | CHAMPIONX LLC (US) | 2025-07-15 | — | — | US | claimed |
| EP-4507722-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | Bluewillow Biologics, Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| WO-1999008112-A1 | METHODS OF IDENTIFYING BIOLOGICAL AGENT COMPOSITIONS | SUPRATEK PHARMA INC. (CA) | 1999-02-18 | — | — | WO | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0647141-A4 | NONAQUEOUS COLD STERILANT. | SIMMONS PAUL L (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0647141-A1 | NONAQUEOUS COLD STERILANT | SIMMONS, Paul L. (US) | 1995-04-12 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| WO-1994000157-A1 | NONAQUEOUS COLD STERILANT | SIMMONS PAUL L (US) | 1994-01-06 | — | — | WO | claimed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | claimed |
| US-4711959-A | REACTING 2-ALKYLSULPHONYL-PYRIMIDINE WITH CYANAMIDE OR METAL SALT OF CYANAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1987-12-08 | — | — | US | claimed |
| US-4157312-A | QUATERNARY AMMONIUM, METAL CHELATE, SWEETENING | UOP INC. (US) | 1979-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144251-A1 | ANTIMICROBIAL NANOCLAYS COMPRISING CATIONIC ANTIMICROBIALS, METHOD OF PREPARATION AND USES THEREOF | KLF10, SLC11A2, SLC7A11 | MMP1 3820/4885HTR2A 4356/4885KCNH2 99/4885 |
| US-12546718-B2 | Silane-fluorophore complex indicator fluoride measurement | DNMT3B, FLNB, MMAB | MMP1 2766/4885HTR2A 2907/4885KCNH2 491/4885 |
| US-20250359545-A1 | Anti-pathogenic aerosol compositions | ACIN1, POLR1C, POLH | MMP1 968/4885HTR2A 4800/4885KCNH2 1306/4885 |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CD14, CD47, MYD88 | MMP1 4291/4885HTR2A 2832/4885KCNH2 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.